Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition
Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology, for up to 450 million CHF. T3 Pharma’s innovative technology uses live bacteria to deliver immune-modulating proteins directly to cancer cells, advancing cancer treatment methodologies.
Enhancing Cancer Immunotherapy Treatments
Despite the progress in cancer treatments, long-term remissions only occur in a small percentage of patients. Boehringer Ingelheim aims to increase this rate by integrating T3 Pharma’s technology with its existing immuno-oncology platforms, including T-Cell Engagers, oncolytic viruses, and cancer vaccines.
T3 Pharma’s Pioneering Technology
T3 Pharma’s unique platform utilizes engineered Yersinia enterocolitica bacteria to deliver bioactive proteins into the tumor micro-environment. This approach enables the design of combination therapies in a single agent, targeting solid cancers effectively.
Boehringer Ingelheim Acquires T3 Pharmaceuticals for Up to 450 Million CHF. Photo courtesy of Madras150/Wikimedia Commons.
Leaders’ Insights on the Collaboration
Michel Pairet, a board member at Boehringer Ingelheim, highlighted the synergy of T3 Pharma’s technology with the company’s R&D programs. Simon Ittig, CEO of T3 Pharma, expressed enthusiasm about accelerating the development of their platform under Boehringer Ingelheim’s umbrella.
Boehringer Ingelheim’s Comprehensive Approach to Cancer Therapy
Boehringer Ingelheim adopts a holistic approach to cancer therapy, combining cancer cell-directed treatments with immuno-oncology strategies. The company is committed to developing smart combinations that offer transformative treatments for cancer patients.
Venture Fund and Global Network
Through its Boehringer Ingelheim Venture Fund, a main investor in T3 Pharma, the company collaborates with leading academic and industry partners worldwide, continuously exploring emerging science in cancer therapy.
T3 Pharma’s Continued Operations in Basel
Headquartered in Allschwil near Basel, Switzerland, T3 Pharma will maintain its operations in the Basel region following the acquisition, continuing to contribute to the Basel biotech industry.